Alnylam Pharmaceuticals (ALNY) Revenue (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Revenue (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.46 Bn | 34.45 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39% |
| Dec 31, 2025 | -12.17% |
| Sep 30, 2025 | 61.44% |
| Jun 30, 2025 | 30.21% |
| Mar 31, 2025 | 0.17% |
| Dec 31, 2024 | 18.42% |
| Sep 30, 2024 | -24.08% |
| Jun 30, 2024 | 33.48% |
| Mar 31, 2024 | 12.42% |
| Dec 31, 2023 | -41.41% |
| Sep 30, 2023 | 135.46% |
| Jun 30, 2023 | -0.17% |
| Mar 31, 2023 | -4.70% |
| Dec 31, 2022 | 26.76% |
| Sep 30, 2022 | 17.56% |
| Jun 30, 2022 | 5.42% |
| Mar 31, 2022 | -17.51% |
| Dec 31, 2021 | 37.79% |
| Sep 30, 2021 | -14.93% |
| Jun 30, 2021 | 24.21% |